100

Aya Hariu1, Yukiko Shirahata1, Kayo Shinohara1

  • 1Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency, 3-3-2, Kasumigaseki, Chiyoda-Ku, Tokyo, 100-0013, Japan.

The AAPS journal
|June 4, 2025
PubMed
概括

这项研究分析了日本对单克隆抗体 (mAbs) 的批准,包括诸如抗体-药物合物 (ADC) 等修饰型. 它追踪了抗体批准的趋势,以了解它们对公共卫生的影响.